MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 44 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,352,250 | +277.6% | 234,250 | +237.8% | 0.03% | +237.5% |
| Q2 2023 | $3,536,391 | -16.4% | 69,341 | -64.9% | 0.01% | -27.3% |
| Q1 2023 | $4,228,953 | +84.8% | 197,707 | -9.3% | 0.01% | +83.3% |
| Q4 2022 | $2,288,990 | +187.9% | 217,999 | +118.3% | 0.01% | +200.0% |
| Q3 2022 | $795,000 | – | 99,874 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 21,751,284 | $1,239,823,188 | 33.43% |
| Cormorant Asset Management, LP | 8,142,100 | $464,099,700 | 27.07% |
| Ally Bridge Group (NY) LLC | 183,105 | $10,436,985 | 12.25% |
| Finepoint Capital LP | 331,416 | $18,890,712 | 9.41% |
| Ghost Tree Capital, LLC | 330,000 | $18,810,000 | 6.19% |
| 5AM Venture Management, LLC | 313,210 | $17,852,970 | 5.14% |
| Ghost Tree Capital, LLC | 250,000 | $14,250,000 | 4.69% |
| MPM BioImpact LLC | 294,190 | $16,768,830 | 4.48% |
| Integral Health Asset Management, LLC | 500,000 | $28,500,000 | 3.95% |
| Altium Capital Management LP | 88,000 | $5,016,000 | 2.62% |